Yep, that's been my view. Anyone who wants to build a large position (300k+) is going to have to move the market 10%+ due to illiquidity on the sell side. As others have pointed out, the lack of that chi-x based program trading has allowed the stock to start trading up.
I'm looking for 20 cents in 1H14. A licensing agreement for PAT-SC1, further clarity on Onyx trial and full data on 4th cohort (and the ability to market it, submit for peer review etc) will all see the stock run IMO.
One question for PAB holders, does anyone know what happened with the 4th patient in the 4th cohort? I was wondering whether they'd applied another dosage due to positive response, but couldn't wait for the results as they wanted to get the results out during the rights issue? I'll be very interested to see the full data released. Plenty of coys doing deals at the phase II stage, PAB could easily be one of them!
GLTA
PAB Price at posting:
5.2¢ Sentiment: Buy Disclosure: Held
